An Open-label, Single Center Phase Ib Study of TEW-7197 (Vactosertib) Plus Weekly Paclitaxel as Second-line Treatment for Metastatic Gastric Adenocarcinoma
Phase of Trial: Phase I
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Vactosertib (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions
- Sponsors MedPacto
- 29 Oct 2019 Planned End Date changed from 20 May 2020 to 20 Jun 2022.
- 29 Oct 2019 Planned primary completion date changed from 20 May 2019 to 20 Dec 2021.
- 15 Oct 2018 New trial record